(Q36662024)

English

Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients

scientific article published on 27 March 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

author name string

Nicolae Leca

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Kimberly A Muczynski

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Jonathan A Jefferson

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Ian H de Boer

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Jolanta Kowalewska

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Elizabeth A Kendrick

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Raimund Pichler

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Connie L Davis

8

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

publication date

27 March 2008

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Clinical Journal of the American Society of Nephrology

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

829-835

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

30 September 2017

The incidence of pancytopenia in patients taking leflunomide alone or with methotrexate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

30 September 2017

Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

30 September 2017

De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

30 September 2017

Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

30 September 2017

De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

30 September 2017

Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

30 September 2017

Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

30 September 2017

The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

30 September 2017

Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

30 September 2017

The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

30 September 2017

Leflunomide interferes with pyrimidine nucleotide biosynthesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

30 September 2017

Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

30 September 2017

Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

28 June 2018

How is leflunomide prescribed and used in Australia? Analysis of prescribing and adverse effect reporting.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

20 September 2018

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

20 September 2018

Treatment of renal allograft polyoma BK virus infection with leflunomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

20 September 2018

Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

20 September 2018

Severe hepatotoxicity in a rheumatoid arthritis patient switched from leflunomide to methotrexate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

20 September 2018

Leflunomide for polyomavirus type BK nephropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

20 September 2018

Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

20 September 2018

Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

20 September 2018

Inhibition of angiogenesis-related endothelial activity by the experimental immunosuppressive agent leflunomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

20 September 2018

Quantitation of BK virus load in serum for the diagnosis of BK virus-associated nephropathy in renal transplant recipients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386698

20 September 2018

Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18372319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide

1 reference

https://pubmed.ncbi.nlm.nih.gov/18372319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An evaluation of leflunomide in the canine renal transplantation model

1 reference

https://pubmed.ncbi.nlm.nih.gov/18372319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Leflunomide-Induced Pneumonitis in a Patient with Rheumatoid Arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18372319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BK-related polyomavirus vasculopathy in a renal-transplant recipient

1 reference

https://pubmed.ncbi.nlm.nih.gov/18372319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of Protein Tyrosine Phosphorylation in T Cells by a Novel Immunosuppressive Agent, Leflunomide

1 reference

https://pubmed.ncbi.nlm.nih.gov/18372319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunosuppressive effects of leflunomide in experimental chronic vascular rejection

1 reference

https://pubmed.ncbi.nlm.nih.gov/18372319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peripheral neuropathy associated with leflunomide: is there a risk patient profile?

1 reference

https://pubmed.ncbi.nlm.nih.gov/18372319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production

1 reference

https://pubmed.ncbi.nlm.nih.gov/18372319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Leflunomide in experimental transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine

1 reference

https://pubmed.ncbi.nlm.nih.gov/18372319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulation of B cell function by the immunosuppressive agent leflunomide

1 reference

https://pubmed.ncbi.nlm.nih.gov/18372319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Leflunomide-induced peripheral neuropathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18372319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/18372319

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2215/CJN.03930907

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36662024&oldid=1643421963"